Acadia Pharmaceuticals Shares Rise Following Oral Arguments in Nuplazid Patent Appeal
Acadia Pharmaceuticals (ACAD) saw positive stock movement on Tuesday following oral arguments in an appellate court regarding the patent protection of its lead product, Nuplazid. The legal proceedings center on a challenge to a lower court's decision that had previously upheld one of Acadia’s key U.S. patents. The outcome of this appeal is critical for the company, as the patent provides significant market exclusivity for Nuplazid. Investors are closely monitoring the case to determine if the current patent protections will remain intact or if competitors may gain earlier access to the market.
Tickers: $ACAD
Topics: court ruling intellectual property patent litigation